Riggs BL, Melton LJ. Involutional osteoporosis. N Engl J Med 1986; 314: 1676-86.

Melton LJ IIIrd. Etiology, diagnosis and management. In: Riggs B, Melton LI, eds. Epidemiology of Fractures. New York: Raven Press, 1988: 133-54.

National Osteoporosis Foundation. Disease statis- tics.

National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. Washington, DC: National Osteoporosis Foundation, 2002.

Melton LJ 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992; 7: 1005-10.

Kanis JA, Johnell O, Oden A et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporosis Int 2000; 11: 669-74.

Consensus conference: Osteoporosis. JAMA 1984; 252: 99-802.

Melton LJ IIIrd. Hip fractures: a worldwide problem today and tomorrow. Bone 1993; 14 (Suppl 1): S1-8.

Grimley Evans J. The significance of osteoporosis. In: Smith R, ed. Osteoporosis. London: Royal College of Physicians, 1990: 1-8.

Alffram PS, Bauer G. Epidemiology of fractures of the forearm. J Bone Joint Surg 1962; 44 (A): 105-14.

Office of Population Censuses and Surveys. Hospital Inpatient Enquiry, 1985. London: HMSO, 1987.

Stevenson JC. HRT, osteoporosis and regulatory authorities. Quis custodiat ipsos custodies? Hum Reprod 2006; 21: 1668-71.

Spector TD, Cooper C, Fenton Lewis A. Trends in admissions for hip fracture in England and Wales. BMJ 1990; 300: 173-4.

Boyce WJ, Vessey MP. Rising incidence of fracture of the proximal femur. Lancet 1985; 1: 150-1.

Lindsay R, Hart DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984; 63: 759-63.

Grimley Evans J, Prudham D, Wandles I. A pro- spective study of fractured proximal femur: Incidence and outcome. Public Health (London) 1979; 93: 235-41.

Nordin BEC, Crilly RG, Smith DA. Osteoporosis. In: Nordin B, ed. Metabolic Bone and Stone Disease. Edinburgh: Churchill Livingstone, 1984: 1-70.

Law MR, Wald NJ, Meade TW. Strategies for pre- vention of osteoporosis and hip fracture. BMJ 1991; 303: 453-9.

Miller CW. Survival and ambulation following hip fractures. J Bone Joint Surg 1978; 60 (A): 930-4.

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis and therapy. JAMA 2001; 285: 320-3.

Smith RW, Risek J. Epidemiological studies of osteoporosis in women of Puerto Rico and south- western Michigan. Clin Orthop 1962; 45: 31-48.

O'Neill TW, Cockerill W, Matthis C et al. Back pain, disability, and radiographic vertebral frac- ture in European women: a prospective study. Osteoporos Int 2004; 15: 760-5.

Lindsay R. Pathogenesis, detection and prevention of postmenopausal osteoporosis. In: Studd J, Whitehead M, eds. The Menopause. Oxford: Blackwell Scientific Publications, 1988: 156-67.

Obrant K, Bengnér U, Johnell O et al. Increasing age-adjusted risk of fragility fractures: a sign of increasing osteoporosis in successive generations? Calcif Tissue Int 1989; 44: 157-67.

Kanis JA, Johnell O, Oden A et al. Epidemiology of osteoporosis and fracture in men. Calcif Tissue Int 2004; 75: 90-9.

Leichter I, Margulies JY, Weinreb A et al. The relationship between bone density, mineral con- tent, and mechanical strength in the femoral neck. Clin Orthop 1982; 163: 272-81.

Dalen N, Hellstrom L-G, Jacobson B. Bone min- eral content and mechanical strength of the femo- ral neck. Acta Orthop Scand 1976; 47: 503-8.

Hui SL, Slemenda CW, Johnson CC Jr. Age and bone mass as predictors of fracture in a prospec- tive study. J Clin Invest 1988; 81: 1804-9.

Gardsell P, Johnell O, Nilsson BE. Predicting frac- tures in women using forearm bone densitome- try. Calcif Tissue Int 1989; 44: 355-61.

Browner WS, Cummings SR, Genat HK. Bone mineral density and fractures of the wrist and humerus in elderly women: a prospective study. J Bone Miner Res 1989; 4 (Suppl): S171.

Cummings SR, Black DM, Nevitt MC et al. Appendicular bone density and age predict hip fractures in women. JAMA 1990; 263: 665-8.

Stevenson JC, Banks LM, Spinks TJ et al. Regional and total skeletal measurements in the early post- menopause. J Clin Invest 1987; 80: 258-62.

Ott SM, Kilcoyne RF, Chesnut CH IIIrd. Ability of four different techniques of measuring bone mass to diagnose vertebral fractures in postmenopausal women. J Bone Miner Res 1987; 2: 201-10.

Mazess RB, Barden H, Ettinger M et al. Bone density of the radius, spine, and proximal femur in oste- opororsis. J Bone Miner Res 1988; 3: 13-18.

Riggs BL, Wahner HW, Seeman E et al. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the post- menopausal and senile osteoporosis syndromes. J Clin Invest 1982; 70: 716-23.

Nordin BEC, Wishart JM, Horowitz M et al. The relation between forearm and vertebral mineral density and fractures in postmenopausal women. Bone Miner 1988; 5: 21-33.

Eastell R, Wahner HW, O'Fallon WM et al. Unequal decrease in bone density of lumbar spine and ultradistal radius in Colles' and vertebral frac- ture syndromes. J Clin Invest 1989; 83: 168-74.

Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density pre- dict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-9.

Boonen S, Koutri R, Dequeker J et al. Measurement of femoral geometry in type I and type II oste- oporosis: differences in hip axis length consistent with heterogeneity in the patho genesis of oste- oporotic fractures. J Bone Miner Res 1995; 10: 1908-12.

El-Kaissi S, Pasco JA, Henry MJ et al. Femoral neck geometry and hip fracture risk: the Geelong oste- oporosis study. Osteoporos Int 2005; 16: 1299-303.

Crabtree NJ, Kroger H, Martin A et al. Improving risk assessment: hip geometry, bone mineral dis- tribution and bone strength in hip fracture cases and controls. The EPOS study. European Prospective Osteoporosis International 2002; 13: 48-54.

Chevalley T, Rizzoli R, Nydegger V et al. Preferential low bone mineral density of the femoral neck in patients with a recent fracture of the proximal femur. Osteoporos Int 1991; 1: 147-54.

Eriksson SAV, Wilde TL. Bone mass in women with hip fracture. Orthop Scand 1988; 59: 19-23.

Bohr H, Schaadt O. Bone mineral content of fem- oral bone and the lumbar spine measured in women with fracture of the femoral neck by dual photon absorptiometry. Clin Orthop 1983; 179: 240-5.

Davis JW, Vogel JM, Ross PD, Wasnich RD. Disease versus etiology: the distinction should not be lost in the analysis. J Nucl Med 1989; 112: 1273-6.

Rose G. Sick individuals and sick populations. Int J Epidemiol 1985; 14: 32-8.

Stevenson JC, Marsh MS. Preventing osteoporosis [Letter]. BMJ 1991; 303: 920-1.

Bates DW, Black DM, Cummings SR. Clinical use of bone densitometry: clinical applications. JAMA 2002; 288: 1898-900.

Johnell O, Kanis JA, Black DM et al. Associations between baseline risk factors and vertebral frac- ture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res 2004; 19: 764-72.

Cummings SR, Nevitt MC, Browner WS et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767-73.

Schuit SC, van der Klift M, Weel AE et al. Fracture incidence and association with bone mineral den- sity in elderly men and women: the Rotterdam Study. Bone 2004; 34: 195-202.

Ross PD, Wasnich RD, McClean CJ et al. A model for estimating the potential costs and savings of osteoporosis prevention strategies. Bone 1988; 9: 337-47.

Cauley JA, Zmuda JM, Wisniewski SR et al. Bone mineral density and prevalent vertebral fractures in men and women. Osteoporos Int 2004; 15: 32-7.

Cummings SR. Are patients with hip fractures more osteoporotic? Am J Med 1985; 78: 487-94.

Winner SJ, Morgan A, Grimley Evans J. Perimenopausal risk of falling and incidence of dis- tal forearm fracture. BMJ 1989; 298: 1486-8.

Dargent-Molina P, Favier F, Grandjean H et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Epidémiologie de l'ostéoporose. Lancet 1996; 348: 145-9.

Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a frac- ture. JAMA 2001; 285: 320-3.

Kanis JA, Aaron J, Thavarajah M et al. Osteoporosis: causes and therapeutic implications. In: Smith R, ed. Osteoporosis. London: Royal College of Physicians, 1990: 45-56.

Nevitt MC, Cummings SR. Type of fall and risk of hip and wrist fractures: the study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 1993; 41: 1226-34.

Kanis JA, Johnell O, De Laet C et al. A meta- analysis of previous fracture and subsequent frac- ture risk. Bone 2004; 35: 375-82.

Dempster DW, Shane E. Principles and Practice of Endocrinology and Metabolism. Philadelphia: JB Lippincott Co. 1990: 475-80.

Coe F, Farus MJ, eds. Disorders of Bone and Mineral Metabolism. New York: Raven Press, 1992.

Owen M, Ashton B. Osteogenic differentiation of different skeletal cell populations. In: Ali S, ed. Cell Mediated Calcification and Matrix Vesicles. Amsterdam: Elsevier, 1986: 279-84.

Anderson HC. Matrix vesicle calcification: review and update. Bone Miner Res 1985; 3: 109-49.

Schneider GB, Relfson M, Nicolas J. Pluripotential hemopoietic stem cells give rise to osteoclasts. Am J Anat 1986; 177: 505-12.

Marchisio PC, Cirillo D, Naldini L et al. Cell sub- stratum interaction of cultured avian osteoclasts is mediated by specific adhesion structures. J Cell Biol 1984; 99: 1696-705.

Stevenson JC, Lindsay RL. Osteoporosis. London: Chapman & Hall, 1998.

Vaes G. Cellular biology and biochemical mechanisms of bone resorption. Clin Orthop 1988; 231: 239-71.

Russell RGG, Caswell AM, Hearn PR et al. Calcium in mineralised tissues and pathological calcifica- tion. Br Med Bull 1986; 42: 435-46.

Bord S, Ireland DC, Moffatt P et al. Characterization of osteocrin expression in human bone. J Histochem Cytochem 2005; 53: 1181-7.

Bord S, Frith E, Ireland DC et al. Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL. Bone 2005; 36: 812-19.

Yamaguchi K, Croucher PI, Compston JE. Comparison between the lengths of individual osteoid seams and resorption cavities in human iliac crest cancel- lous bone. Bone Miner 1993; 23: 27-33.

Jones SJ, Boyd A. Experimental study of changes in osteoblastic shape induced by calcitonin and parathyroid extract in an organ culture system. Cell Tissue Res 1976; 169: 449-55.

Russell RGG. Bone cell biology: the role of cytokines and other mediators. In: Smith R, ed. Osteoporosis. London: Royal College of Physicians, 1990; 9-33.

Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115: 3318-25.

Lee K, Jessop H, Suswillo R et al. Endocrinology: bone adaptation requires oestrogen receptor-al- pha. Nature 2003; 424: 389.

Colston KW, King RWB, Hayward J et al. Estrogen receptors and human bone cells: immuno cyto- chemical studies. J Bone Miner Res 1989; 4: 625-31.

Windahl SH, Hollberg K, Vidal O et al. Female estrogen receptor beta-/-mice are partially pro- tected against age-related trabecular bone loss. J Bone Miner Res 2001; 16: 1388-98.

Sims NA, Dupont S, Krust A et al. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone 2002; 30: 18-25.

Gao Y, Qian WP, Dark K et al. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci USA 2004; 101: 16618-23.

Hughes DE, Dai A, Tiffee JC et al. Estrogen pro- motes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996; 2: 1132-6.

Russell RGG, Bunning RAD, Hughes DE et al. Humoral and local factors affecting bone forma- tion and resorption. In: Stevenson J, ed. New Techniques in Metabolic Bone Disease. London: Wright, 1990: 1-20.

Stevenson JC, Abeyasekera G, Hillyard CJ et al. Regulation of calcium-regulating hormones by exogenous sex steroids in early postmenopause. Eur J Clin Invest 1983; 13: 481-7.

Stevenson JC, Abeyasekera G, Hillyard CJ et al. Calcitonin and the calcium-regulating hormones in postmenopausal women: effect of oestrogens. Lancet 1981; 1: 693-5.

Delorme ML, Digioia Y, Fandard J et al. Oestrogens et calcitonie. Ann d'Endo 1976; 37: 503-4.

Hillyard CJ, Stevenson JC, MacIntyre I. Relative deficiency of plasma-calcitonin in normal women. Lancet 1978; 1: 961-2.

Tiegs RD, Barta J, Heath H. Does oral contracep- tive therapy affect calcitonin secretion in premeno- pausal women? Presented at The Endocrine Society, 67th Annual General Meeting, Baltimore, MD, 1985; 50.

Taggart HM, Chesnut CH IIIrd, Ivey JL et al. Deficient calcitonin response to calcium stimula- tion in postmenopausal osteoporosis. Lancet 1982; 1: 475-8.

Tiegs RD, Body JJ, Wahner HW et al. Calcitonin secretion in postmenopausal osteoporosis. N Engl J Med 1985; 312: 1097-100.

Pacifici R, Rifas L, Teitelbaum S et al. Spontaneous release of interleukin-1 from human blood mono- cytes reflects bone formation in idiopathic bone osteoporosis. Proc Natl Acad Sci USA 1987; 84: 4616-20.

Ralston SH. Analysis of gene expression in human bone biopsies by polymerase chain reaction: evi- dence for enhanced cytokine expression in post- menopausal osteoporosis. J Bone Miner Res 1994; 8: 83-90.

Bertolini DR, Nedwin GE, Bringman TS et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 1986; 319: 516-21.

Kimble RB, Matayoshi AB, Vannice JL et al. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology 1995; 136: 3054-61.

Kalu DN, Salerno E, Higami Y et al. In vivo effects of transforming growth factor-beta 2 in ovariect- omized rats. Bone Miner 1993; 22: 209-20.

Hughes DE, Dai A, Tiffee JC et al. Estrogen pro- motes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996; 2: 1132-6.

Ralston SH, Ho LP, Helfrich MH et al. Nitric oxide: a cytokine-induced regulator of bone resorption. J Bone Miner Res 1995; 10: 1040-9.

Ralston SH, Todd D, Helfrich MH et al. Human osteoblast-like cells produce nitric oxide and express inducible nitric oxide synthase. Endocrinology 1994; 135: 330-6.

Ralston SH, Grabowski PS. Mechanisms of cytokine- induced bone resorption; role of nitric oxide, cyclic guanosine monophosphate and prostaglandins. Bone 1996; 19: 29-33.

Evans DM, Ralston SH. Nitric oxide and bone. J Bone Miner Res 1996; 11: 300-5.

Schlesinger PH, Mattsson JP, Blair HC. Osteoclastic acid transport: mechanism and implications for physiological and pharmacological regulation. Miner Electrolyte Metab 1994; 20: 31-9.

David P, Nguyen H, Barbier A et al. The bisphos- phonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J Bone Miner Res 1996; 11: 1498-507.

Suda T, Takahashi N, Udagawa N et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-57.

Bekker PJ, Holloway DL, Rasmussen AS et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059-66.

Khosla S, Amighi HM, Melton LJ et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 2002; 13: 394-9.

Khosla S, Riggs BL, Atkinson EJ et al. Relationship of estrogen receptor genotypes to bone mineral density and to rates of bone loss in men. J Clin Endocrinol Metab 2004; 89: 1808-16.

Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun 2005; 328: 688-96.

Wasnich RD, Ross PD, Davis JW, Vogel JM. A comparison of single and multisite BMC measure- ments for assessment of spine fracture probability. J Nucl Med 1989; 30: 1166-71.

Stevenson JC, Lees B, Devenport M et al. Determinants of bone density in normal women: risk factors for future osteoporosis? BMJ 1989; 298: 924-8.

Thomsen K, Gotfredsen A, Christiansen C. Is postmenopausal bone loss an age-related phe- nomenon? Calcif Tissue Int 1986; 39: 132-27.

Guesens P, Dequeker J, Verstraeten A et al. Age, sex-and menopause-related changes of vertebral and peripheral bone: population study using dual- photon absorptiometry and radiogrammetry. J Nucl Med 1986; 27: 1540-9.

Smith DM, Nance WE, Kang KW et al. Genetic factors in determining bone mass. J Clin Invest 1973; 52: 2800-8.

Seeman E, Tsalamandris C, Formica C et al. Reduced femoral neck bone density in the daughters of women with hip fractures: the role of low peak bone density in the pathogenesis of osteoporosis. J Bone Miner Res 1994; 9: 739-43.

Cohn SH, Abesamis C, Yamasura S et al. Comparative skeletal mass and radial bone mineral content in black and white women. Metabolism 1977; 26: 171-8.

Kanders B, Lindsay R, Dempster DW et al. Determinants of bone mass in young healthy women. In: Christiansen C, ed. Osteoporosis. Aalborg: Stiftsbogtrykkeri, 1984: 337-40.

Sandler RB, Slemenda CW, LaPorte RE et al. Postmenopausal bone density and milk consump- tion in childhood and adolescence. Am J Clin Nutr 1985; 42: 270-4.

Soroko S, Holbrook TL, Edelstein S et al. Lifetime milk consumption and bone mineral density in older women. Am J Public Health 1994; 84: 1319-22.

Kanis JA, Passmore R. Calcium supplementation of the diet-1. BMJ 1989; 298: 137-40.

Greendale GA, Barrett-Connor E, Edelstein S et al. Lifetime leisure exercise and osteoporosis. The Rancho Bernardo study. Am J Epidemiol 1995; 141: 951-9.

Stevenson JC, Less B, Fielding C et al. Exercise and the skeleton. In Smith R, ed. Osteoporosis. London: Royal College of Physicians, 1990: 119-24.

Jaglal SB, Kreiger N, Darlington GA. Lifetime occupational physical activity and risk of hip frac- ture in women. Ann Epidemiol 1995; 5: 321-4.

Cooper C, Cawley M, Bhalla A et al. Childhood growth, physical activity, and peak bone mass in women. J Bone Miner Res 1995; 10: 940-7.

McGuigan FEA, Murray L, Gallagher A et al. Genetic and environmental determinants of peak bone mass in young men and women. J Bone Miner Res 2002; 17: 1273-9.

Lloyd T, Myers C, Buchanan JR, Demers LM. Collegiate women athletes with irregular menses during adolescence have decreased bone density. Obstet Gynecol 1988; 72: 639-42.

Lindberg JS, Fears WB, Hunt MM et al. Exercise induced amenorrhea and bone density. Ann Intern Med 1984; 101: 258-60.

Drinkwater BL, Nilson K, Chesnut CH IIIrd et al. Bone mineral density of amenorrheic and eumen- orrheic athletes. N Engl J Med 1984; 311: 277-81.

Slemender CW, Hui SL, Longcope C, Johnson CC. Cigarette smoking. Obesity and bone mass. J Bone Miner Res 1989; 4: 737-41.

Baron BA. Smoking and estrogen-related disease. Am J Epidemiol 1984; 119: 9-22.

Rigotti NA. Cigarette smoking and body weight. N Engl J Med 1989; 320: 931-3.

Krall EA, Dawson-Hughes B. Smoking increases bone loss and decreases intestinal calcium absorp- tion. J Bone Miner Res 1999; 14: 215-20.

Law MR, Hackshaw AK. A meta-analysis of ciga- rette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 1997; 315: 841-6.

Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. N Engl J Med 1994; 330: 387-92.

Saville PD. Changes in bone mass with age and alcoholism. J Bone Joint Surg 1965; 47: 492-9.

De Vernejoul MC, Bielakoff J, Herve M et al. Evidence for defective osteoblastic function. A role for alco- hol and tobacco consumption in osteoporosis in middle aged men. Clin Orthop 1983; 179: 107-15.

Tuppurainen M, Kroger H, Honkanen R et al. Risks of perimenopausal fractures -a prospective population-based study. Acta Obstet Gynecol Scand 1995; 74: 624-8.

Hannan MT, Felson DT, Dawson-Hughes B et al. Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 2000; 15: 710-20.

Murphy S, Shaw KT, May H, Compston JE. Parity and bone density in middle age women. Osteoporos Int 1994; 4: 162-6.

Prince RL, Dick I, Devine A et al. The effects of menopause and age on calcitropic hormones: a cross-sectional study of 655 healthy women aged 35 to 90. J Bone Miner Res 1995; 10: 835-42.

Brazier M, Kamel S, Maamer M et al. The markers of bone remodeling in the elderly subject: effects of vitamin D insufficiency and its correction. J Bone Miner Res 1995; 10: 1753-61.

Simpson RU, Thomas GA, Arnold AJ. Identification of 1,25-dihydroxyvitamin D3 receptors and activ- ities in muscle. J Biol Chem 1985; 260: 8882-91.

Costa EM, Blau HM, Feldman D. 1,25-dihydroxyvi- tamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. Endocrinology 1986; 119: 2214-20.

Haddad JG, Walgate J, Min C, Hahn TJ. Vitamin D metabolite binding proteins in human tissue. Biochem Biophys Acta 1976; 444: 921-5.

Schott G, Wills M. Muscle weakness in osteomal- acia. Lancet 1976; 2: 626-9.

Boland R. Role of vitamin D in skeletal muscle func- tion. Endocr Rev 1986; 7: 434-8.

Pfeifer M, Begerow B, Minne HW et al. Vitamin D status, trunk muscle strength, body sway, falls, and fractures among 237 postmenopausal women with osteoporosis. Exp Clin Endocrinol Diabetes 2001; 109: 87-92.

Sambrook PN, Chen JS, March LM et al. Serum parathyroid hormone predicts time to fall inde- pendent of vitamin D status in a frail elderly pop- ulation. J Clin Endocrinol Metab 2004; 89: 1572-6.

Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004; 291: 1999-2006.

Bischoff HA, Stahelin HB, Dick W et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003; 18: 343-51.

Dukas L, Bischoff HA, Lindpainter LS et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004; 52: 230-6.

Riggs BL, Wahner HW, Seeman E et al. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the post- menopausal and senile osteoporosis syndromes. J Clin Invest 1982; 70: 716-23.

Riggs BL, Wahner HW, Dunn WL et al. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest 1981; 67: 328-35.

Nordin BEC, Marshall DH, Francis RM, Crilly RG. The effect of sex steroid and corticosteroid hor- mones on bone. J Steroid Biochem 1981; 15: 171-4.

Abdallah H, Hart DM, Lindsay R. Differential bone loss and effects of long-term oestrogen therapy according to time of introduction of therapy after oophorectomy. In: Christiansen C, Arnaud C, Nordin B et al, eds. Osteoporosis. Glostrup: Glostrup Hospital, 1984: 621-3.

Krolner B, Nielsen SP. Bone mineral content of the lumbar spine in normal and osteoporotic women: cross-sectional and longitudinal studies. Clin Sci 1982; 62: 329-36.

Riggs BL, Jowsey J, Kelly PJ et al. Effect of sex hor- mones on bone in primary osteoporosis. J Clin Invest 1969; 48: 1065-72.

Nordin BEC, Aaron J, Speed R, Crilly RG. Bone formation and resorption as the determinants of trabecular bone volume in postmenopausal osteo- porosis. Lancet 1981; 2: 277-9.

Heaney RP, Recker RR, Saville PD. Menopausal changes in bone remodelling. J Lab Clin Med 1978; 92: 964-70.

Hansen JW, Gordan GS, Prussin SG. Direct mea- surement of osteolysis in man. J Clin Invest 1973; 52: 304-15.

Stevenson JC, Banks LM, Spinks TJ et al. Regional and total skeletal measurements in the early post- menopause. J Clin Invest 1987; 80: 258-62.

Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low dosage estrogen with calcium. Ann Intern Med 1987; 106: 40-5.

Stevenson JC, Lees B, Banks LM, Whitehead MI. Assessment of therapeutic options for prevention of bone loss. In: Christiansen C, Johansen J, Riis BJ, eds. Osteoporosis. Viborg: Norhaven Bogtrykken A/S, 1987: 392-3.

Genant HK, Cann CE, Ettinger B, Gordan GS. Quantitative computed tomography of vertebral spongiosa: a sensitive method of detecting early bone loss after oophorectomy. Ann Intern Med 1982; 97: 699-705.

Christiansen C, Christiansen MS, Transbøl I. Bone mass in postmenopausal women after withdrawal of oestrogen replacement therapy. Lancet 1981; 1: 459-61.

Lindsay R, Hart DM, Aitken JM et al. Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet 1976; 1: 1038-41.

Riis BJ. The role of bone loss. Am J Med 1995; 98: 29S-32S.

Christiansen C. What should be done at the time of menopause? Am J Med 1995; 98: 56S-9S.

Christiansen C, Riis BJ, Rødbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987; 1: 1105-7.

Poortman J, Thijssen JHH, de Waard F. Plasma oestrone, oestradiol and androstanedione levels in postmenopausal women: relation to body weight and height. Maturitas 1981; 3: 65-71.

MacDonald PC, Edman CD, Hemsell DL et al. Effect of obesity on conversion of plasma andros- tanedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1978; 130: 448-55.

Christiansen C. Prophylactic treatment for age- related bone loss in women. In: Christiansen C, Arnaud CD, Nordin BEC et al, eds. Proceedings of the International Symposium on Osteoporosis. Copenhagen: Aalborg Stiftsbogtrykkeri, 1984; 2: 587-93.

Johnston CC Jr, Hui SL, Witt RM et al. Early meno- pausal changes in bone mass and sex steroids. J Clin Endocrinol Metab 1985; 61: 905-11.

Slemender C, Hui SL, Longcope C, Johnston CC. Sex steroids and bone mass: a study about the time of menopause. J Clin Invest 1987; 80: 1261-9.

Clements D, Compston JE, Evans C, Evans WD. Bone loss in normal British women; a 5-year follow- up. Br J Radiol 1993; 66: 1134-7.

Pugh JW, Rose RM, Radin EL. Elastic and viscoelas- tic properties of bone. J Biomech 1973; 6: 475-85.

Compston JE, Mellish RWE, Garrahan NJ. Age- related changes in the iliac crest trabecular micro- anatomic bone structure in man. Bone 1978; 8: 289-92.

Compston JE. Structural mechanisms of trabecular bone loss. In: Smith R, ed. Osteoporosis. London: Royal College of Physicians, 1990: 35-43.

Chappard D, Legrand E, Haettich B et al. Fractal dimension of trabecular bone: comparison of three histomorphometric computed techniques for measuring the architectural two-dimensional complexity. J Pathol 2001; 195: 515-21.

Oka K, Kumasaka S, Kashima I. Assessment of bone feature parameters from lumbar trabecular skel- etal patterns using mathematical morphology image processing. J Bone Miner Metab 2002; 20: 201-8.

Banse X, Devogelaer JP, Lafosse A et al. Cross-link profile of bone collagen correlates with structural organization of trabeculae. Bone 2002; 31: 70-6.

Miki T, Nakatsuka K, Naka H et al. Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomor- phometry and microstructural analysis of iliac tra- becular bone before and after 1 year of treatment. J Bone Miner Metab 2004; 22: 569-76. REFERENCES

Peacock M. Hypercalcaemia and calcium homeo- stasis. Metab Bone Dis Rel Res 1980; 2: 143-50.

Marshall RW, Francis RM, Hodgkinson A. Plasma total and ionised calcium, albumin and globulin concentrations in pre-and postmenopausal women and the effects of oestrogen administra- tion. Clin Chim Acta 1982; 122: 283-7.

Stevenson JC. Vitamin D in postmenopausal women. In: Duursma S, van der Sluys Veer J, eds. Vitamin D. Utrecht: Wetenschappelijke uitgerij Bunge, 1983: 43-55.

Heaney RP, Recker RR, Saville PD. Menopausal changes in calcium balance performance. J Lab Clin Med 1978; 92: 953-63.

Riggs BL, Jowsey J, Kelley PJ, Arnaud CD. Role of hormonal factors in the pathogenesis of post- menopausal osteoporosis. Isr J Med Sci 1976; 12: 615-19.

Nordin BEC. Osteomalacia, osteoporosis and cal- cium deficiency. Clin Orthop 1960; 17: 235-57.

Riggs BL, Melton LJ. Evidence for two distinct syn- dromes of involutional osteoporosis. Am J Med 1983; 75: 899-901.

Reeve J. The use of biochemical and isotopic stud- ies in the investigation of bone disorders. In: Stevenson J, ed. New Techniques in Metabolic Bone Disease. London: Wright, 1990: 92-109.

Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Incsreased bone turnover in late postmeno- pausal women is a major determinant of osteopo- rosis. J Bone Miner Res 1996; 11: 337-49.

Stepan JJ, Volek V, Kolar JA. A modified inactiva- tion inhibition method for determining the serum activity of alkaline phosphatase isoenzymes. Clin Chim Acta 1976; 69: 1-9.

Moss DW, King EJ. Properties of alkaline phos- phatase fractions separated by starch gel electro- phoresis. Biochemistry 1962; 84: 192-5.

Posen S, Neale FC, Clubb JS. Heat inactivation in the study of human alkaline phosphatases. Ann Intern Med 1965; 62: 1234-43.

Christiansen C, Riis BJ. Risk assessment using bio- chemical analysis. In: Smith R, ed. Osteoporosis. London: Royal College of Physicians, 1990: 158-61.

Eftekharian MM, Moazzeni SM, Pourfathollah AA, Khabiri, AR. Production of monoclonal antibody against alkaline phosphatase. Hum Antibodies 2005; 14: 17-21.

Garnero P, Delmas PD. New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996; 59(7): 2-9.

Hasling C, Eriksen EF, Melkko J et al. Effects of a combined estrogen-gestagen regimen on serum levels of the carboxy-terminal propeptide of human type I procollagen in osteoporosis. J Bone Miner Res 1991; 6: 1295-300.

Deal C, Omizo M, Schwartz EN et al. Combination teriparatide and raloxifene therapy for postmeno- pausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005; 20: 1905-11.

Chen JS, Cameron ID, Cumming RG et al. Effect of age-related chronic immobility on markers of bone turnover. J Bone Miner Res 2006; 21: 324-31.

Floter A, Nathorst-Boos J, Carlstrom K et al. Effects of combined estrogen/testosterone therapy on bone and body composition in oophorectomized women. Gynecol Endocrinol 2005; 20: 155-60.

Dobnig H, Sipos A, Jiang Y et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teri- paratide therapy. J Clin Endocrinol Metab 2005; 90: 3970-7.

Brown JP, Delmas PD, Malval L et al. Serum bone Gla protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984; 1: 1091-3.

Miura H, Yamamoto I, Yuu I et al. Estimation of bone mineral density and bone loss by means of bone metabolic markers in postmenopausal women. Endocrinol Jpn 1995; 42: 797-802.

Dresner-Pollak R, Parker RA, Poku M et al. Biochemical markers of bone turnover reflect fem- oral bone loss in elderly women. Calcif Tissue Int 1996; 59: 328-33.

Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-con- trolled, randomized clinical trial. J Clin Endocrinol Metab 2005; 90: 2762-7.

Kemmler W, Lauber D, Weineck J et al. Benefits of 2 years of intense exercise on bone density, physical fitness, and blood lipids in early post- menopausal osteopenic women: results of the Erlangen Fitness Osteoporosis Prevention Study (EFOPS). Arch Intern Med 2004; 164: 1084-91.

Pagani F, Francucci CM, Moro L. Markers of bone turnover: biochemical and clinical perspectives. J Endocrinol Invest 2005; 28 (10 Suppl): 8-13.

Seibel MJ, Cosman F, Shen V et al. Urinary hydroxy- pyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopaus- al osteoporosis. J Bone Miner Res 1993; 8: 881-9.

Schlemmer A, Hassager C, Delmas PD et al. Urinary excretion of pyridinium cross-links in healthy women; the long-term effects of menopause and oestrogen/progesterone therapy. Clin Endocrinol 1994; 40: 777-82.

Okabe R, Inaba M, Nakatsuka K et al. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replace- ment therapy; comparison with serum carboxy- terminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab 2004; 22: 127-31.

Eastell R, Robins SP, Colwel T et al. Evaluation of bone turnover in type I osteoporosis using bio- chemical markers specific for both bone forma- tion and bone resorption. Osteoporos Int 1993; 3: 255-60.

Charles P, Mosekilde L, Risteli L et al. Assessment of bone remodelling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner 1994; 24: 81-94.

Valimaki MJ, Tahtela R, Jones JD et al. Bone resorption in healthy and osteoporotic post- menopausal women: comparison markers for serum carboxy-terminal telopeptide of type I col- lagen and urinary pyridinium cross-links. Eur J Endocrinol 1994; 131: 258-62.

Eriksen EF, Charles P, Melsen F et al. Serum mark- ers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 1993; 8: 127-32.

Hassager C, Jensen LT, Podenphant J et al. The carboxy-terminal pyridinoline cross-linked telo- peptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decano- ate and hormone replacement therapy. Calcif Tissue Int 1994; 54: 30-3.

Han KO, Choi JT, Choi HA et al. The changes in circulating osteoprotegerin after hormone thera- py in postmenopausal women and their relation- ship with oestrogen responsiveness on bone. Clin Endocrinol 2005; 62: 349-53.

Ravn P, Warming L, Christgau S et al. The effect on cartilage of different forms of application of post- menopausal estrogen therapy: comparison of oral and transdermal therapy. Bone 2004; 35: 1216-21.

Khosla S, Peterson JM, Egan K et al. Circulating cytokine levels in osteoporotic and normal women. J Clin Endocrinol Metab 1994; 79: 707-11.

Bettica P, Taylor AK, Talbot J et al. Clinical perfor- mances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteo- porosis. J Clin Endocrinol Metab 1996; 81: 542-6.

Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover mark- ers, or both? J Med 2006; 119 (4 Suppl 1): S25-31. REFERENCES

World Health Organization. Assessment of frac- ture risk and its application to screening for post- menopausal osteoporosis. World Health Organization Technical Report Series. Geneva: WHO, 1994.

Siris ES, Miller PD, Barrett-Connor E et al. Identification and fracture outcomes of undiag- nosed low bone mineral density in postmeno- pausal women. JAMA 2001; 286: 2815-22.

Pasco JA, Seeman E, Henry MJ et al. The popula- tion burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int 2006; 17: 1404-9.

Stulberg BN, Bauer TW, Watson JT, Richmond B. Bone quality. Roentgenographic versus histologic assessment of hip bone structure. Clin Orthop 1989; 240: 200-5.

Hurxthal LM, Vose GP, Dotter WE. Densitometric and visual observations of spinal radiographs. Geriatrics 1969; 24: 93-106.

Stevenson JC, Banks LM, Spinks TJ et al. Regional and total skeletal measurements in the early post- menopause. J Clin Invest 1987; 80: 258-62.

Doyle FH. Involutional osteoporosis. In: MacIntyre I, ed. Clinics in Endocrinology and Metabolism. London: WB Saunders, 1972: 143-67.

Grubb SA, Jacobson PC, Aubrey BJ et al. Bone density in osteoporotic women: a modified distal radius density measurement procedure to develop an 'at risk' value for use in screening women. J Orthop Res 1984; 2: 328-32.

Chrischilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone 1994; 15: 377-86.

Borg J, Mollgaard A, Riis BJ. Single x-ray absorpti- ometry: performance characteristics and compari- son with single-photon absorptiometry. Osteoporos Int 1995; 5: 377-81.

Banks LM, Stevenson JC. Developments in com- puterized axial tomography scanning and its use in bone disease measurement. In: Stevenson J, ed. New Techniques in Metabolic Bone Disease. London: Wright, 1990:138-56.

Lindsay R. Pathogenesis, detection and prevention of postmenopausal osteoporosis. In: Studd J, Whitehead M, eds. The Menopause. Oxford: Blackwell Scientific Publications, 1988: 156-67.

Guglielmi G, Grimston SK, Fischer KC, Pacifici R. Osteoporosis: diagnosis with lateral and posteroan- terior dual x-ray absorptiometry compared with quantitative CT. Radiology 1994; 192: 845-50.

Jergas M, Breitenseher M, Gluer CC et al. Estimates of volumetric bone density from projectional mea- surements improve the discriminatory capability of dual x-ray absorptiometry. J Bone Miner Res 1995; 10: 1101-10.

Briggs AM, Wark JD, Kantor S et al. In vivo intra-operator and inter-operator precision of measuring apparent bone mineral density in ver- tebral subregions using supine lateral dual-energy x-ray absorptiometry. J Clin Densitom 2005; 8: 314-19.

Hamdy RC, Petak SM, Lenchik L; International Society for Clinical Densitometry Position Develop- ment Panel and Scientific Advisory Committee. Which central dual X-ray absorptiometry skeletal sites and regions of interest should be used to determine the diagnosis of osteoporosis? J Clin Densitom 2002; 5 (Suppl): S11-18.

Grampp S, Jergas M, Lang P et al. Quantitative CT assessment of the lumbar spine and radius in patients with osteoporosis. Am J Roentgenol 1996; 167: 133-40.

Grampp S, Lang P, Jergas M et al. Assessment of the skeletal status by peripheral quantitative computed tomography of the forearm: short- term precision in vivo and comparison to dual x-ray absorptiometry. J Bone Miner Res 1995; 10: 1566-76.

Clowes JA, Eastell R, Peel NF. The discriminative ability of peripheral and axial bone measurements to identify proximal femoral, vertebral, distal forearm and proximal humeral fractures: a case control study. Osteoporos Int 2005; 16: 1794-802.

Milos G, Spindler A, Ruegsegger P et al. Cortical and trabecular bone density and structure in anorexia nervosa. Osteoporos Int 2005; 16: 783-90.

Banks LM, Stevenson JC. Modified method of spi- nal computed tomography for trabecular bone mineral measurements. J Comput Assist Tomogr 1986; 10: 463-7.

Sandor T, Felsenberg D, Kalender WA et al. Compact and trabecular components of the spine using quantitative computed tomography. Calcif Tissue Int 1992; 50: 502-6.

Mundinger A, Wiesmeier B, Dinkel E et al. Quantitative image analysis of vertebral body architecture -improved diagnosis in osteoporosis based on high-resolution computed tomography. Br J Radiol 1993; 66: 209-13.

Jiang Y, Zhao J, Liao EY et al. Application of micro- CT assessment of 3-D bone microstructure in preclinical and clinical studies. J Bone Miner Metab 2005; 23 (Suppl): 122-31.

Wehrli FW, Ford JC, Haddad JG. Osteoporosis: clinical assessment with quantitative MR imaging in diagnosis. Radiology 1995; 196: 631-41.

Schick F, Seitz D, Machann J et al. Magnetic reso- nance bone densitometry. Comparison of different methods based on susceptibility. Invest Radiol 1995; 30: 254-65.

Krug R, Banerjee S, Han ET et al. Feasibility of in vivo structural analysis of high-resolution magnetic resonance images of the proximal femur. Osteoporos Int 2005; 16: 1307-14.

Hudelmaier M, Kollstedt A, Lochmuller EM et al. Gender differences in trabecular bone architecture of the distal radius assessed with magnetic resonance imaging and implications for mechanical competence. Osteoporos Int 2005; 16: 1124-33.

Langton CM, Palmer SB, Porter RW. The measure- ment of broadband ultrasonic attenuation in cancellous bone. N Engl J Med 1984; 13: 89-91.

Herd RJ, Ramalingham T, Ryan PJ et al. Measurements of broadband ultrasonic attenuation in the calca- neus in premenopausal and postmenopausal women. Osteoporos Int 1992; 2: 247-51.

Argen M, Karellas A, Leahey D et al. Ultrasound attenuation of the calcaneus: a sensitive and specific discriminator of osteopenia in postmenopausal women. Calcif Tissue Int 1991; 48: 240-4.

Rossman P, Zagzebski J, Mesina C et al. Comparison of speed of sound and ultrasound attenuation in the os calcis to bone density of the radius, femur and lumbar spine. Clin Phys Physiol Meas 1989; 10: 353-60.

McCloskey EV, Murray SA, Miller C et al. Broad- band ultrasound attenuation in the os calcis: rela- tionship to bone mineral at other skeletal sites. Clin Sci 1990; 78: 227-33.

Baran DT, Kelly AM, Karella A et al. Ultrasound attenuation of the os calcis in women with osteo- porosis and hip fractures. Calcif Tissue Int 1988; 43: 138-42.

Massie A, Reid DM, Porter RW. Screening for osteoporosis: comparison between dual-energy x-ray absorptiometry and broadband ultrasound attenuation in 1000 perimenopausal women. Osteoporos Int 1993; 3: 107-10.

Wasnich RD, Ross PD, Hellbrun LK, Vogel JM. Prediction of postmenopausal fracture risk with use of bone mineral measurements. Am J Obstet Gynecol 1985; 153: 745-51.

Gluer CC, Cummings SR, Bauer DC et al. Osteoporosis: ssociation of recent fractures with quantitative US findings. Radiology 1996; 199: 725-32.

Glüer CC, Eastell R, Reid DM et al. Association of five quantitative ultrasound devices and bone den- sitometry with osteoporotic vertebral fractures in population-based sample: the OPUS study. J Bone Miner Res 2004; 19: 782-93.

Frost ML, Blake GM, Fogelman I. Can the WHO criteria for diagnosing osteoporosis be applied to calcaneal quantitative ultrasound? Osteoporos Int 2000; 11: 321-30.

Knapp KM, Blake GM, Spector TD et al. Can the WHO definition of osteoporosis be applied to multi-site axial transmission quantitative ultra- sound? Osteoporos Int 2004; 15: 367-74. REFERENCES

Tuppurainen M, Kroger H, Honkanen R et al. Risks of perimenopausal fractures -a prospec- tive population-based study. Acta Obstet Gynecol Scand 1995; 74: 624-8.

Paganini-Hill A, Ross RK, Gerkins VR et al. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981; 95: 28-31.

Weiss NS, Ure BL, Ballard JH et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980; 303: 1195-8.

Hutchinson TA, Polansky SM, Feinstein AR. Postmenopausal oestrogens protect against fractures of the hip and distal radius: a case- controlled study. Lancet 1979; 2: 705-9.

Ettinger B, Genant HK, Cann CE. Long term estrogen therapy prevents bone loss and fracture. Ann Intern Med 1979; 102: 319-24.

Baron YM, Brincat MP, Galea R, Calleja N. Intervertebral disc height in treated and untreat- ed overweight menopausal women. Hum Reprod 2005; 20: 3566-70.

Lindsay R, Hart DM. The minimum effective dose of estrogen for prevention of postmeno- pausal bone loss. Obstet Gynecol 1984; 63: 759-63.

Christiansen C, Christensen MS, Larsen N-E, Transbol IB. Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose- response relationships in early postmenopausal women. J Clin Endocrinol Metab 1982; 55: 1124-30.

Lees B, Stevenson JC. The prevention of osteo- porosis using sequential low-dose hormone replacement therapy with estradiol-17β and dydrogesterone. Osteoporos Int 2001; 12: 251-8.

Rossouw JE, Anderson GL, Prentice RL et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.

Anderson GL, Limacher M, Assaf AR et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in post- menopausal women with hysterectomy: the Women's Health Initiative randomized con- trolled trial. JAMA 2004; 291: 1701-12.

McKay Hart D, Al-Azzawi F, Farish E. Effect of Ossopan alone, oestradiol implants alone or both therapies combined on bone density and bone biochemistry in oophorectomised women. In: Christiansen C, Johansen J, Riis BJ, eds. Osteoporosis. Copenhagen: Osteopress, 1987.

Ryde SJ, Bowen-Simkins K, Bowen-Simkins P et al. The effect of oestradiol implants on regional and total bone mass: a three-year longitudinal study. Clin Endocrinol 1994; 40: 33-8.

Savvas M, Watson NR, Garnett T et al. Skeletal effects of oral oestrogen compared with subcu- taneous oestrogen and testosterone in post- menopausal women. BMJ 1988; 297: 331-3.

Holland EF, Leather AT, Studd JW. Increase in bone mass of older postmenopausal women with low mineral bone density after one year of percutaneous oestradiol implants. Br J Obstet Gynaecol 1995; 102: 238-42.

Riis BJ, Thomsen K, Strom V, Christiansen C. The effects of percutaneous estradiol and natu- ral progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987; 156: 61-5.

Hillard TC, Whitcroft SJ, Marsh MS et al. Long- term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos Int 1994; 4: 341-8.

Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low dosage estrogen with calcium. Ann Intern Med 1987; 106: 40-5.

Lindsay D, Hart DM, Clark DM. Bone response to termination of oestrogen treatment. Lancet 1978; 1: 1325-7.

Wasnich RD, Bagger YZ, Hosking DJ et al. Early Postmenopausal Intervention Cohort Study Group. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004; 11: 622-30.

Stevenson JC, Kanis JA, Christiansen C. Bone- density measurement [Letter]. Lancet 1992; 339: 370-1.

Bagger YZ, Tankó LB, Alexandersen P et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporo- tic fractures: the PERF study. Bone 2004; 34: 728-35.

Cauley JA, Seeley DG, Ensrud K et al. The Study of Osteoporotic Fractures Research Group. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995; 122: 9-16.

Kanis JA. Treatment of osteoporosis in elderly women. Am J Med 1995; 98: 60-6S.

Ettinger B, Ensrud KE, Wallace R et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004; 104: 443-51.

Vedi S, Crocher PI, Garrahan NJ, Compston JE. Effects of hormone replacement therapy on cancellous bone structure in postmenopausal women. Bone 1996; 19: 69-72.

Stevenson JC. HRT, osteoporosis, and regula- tory authorities. Quis custodiet ipsos custodies? Hum Reprod 2006; 21: 1668-71.

Torgerson DJ, Bell-Sayer SE. Hormone replace- ment therapy and prevention of vertebral frac- tures: a meta-analysis of randomized trials. BMC Musculoskelet Disord 2001; 2: 7.

Torgerson DJ, Bell-Sayer SE. Hormone replace- ment therapy and prevention of non-vertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285: 2891-7.

Delmas DD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-7.

Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with ralox- ifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-45.

Lippman ME, Kreuger KA, Eckert S et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study patients. J Clin Oncol 2001; 19: 3111-16.

Barrett-Connor E, Mosca L, Collins P et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-37.

Stevenson JC, ed. New Techniques in Metabolic Bone Disease. London: Wright, 1990: 63-8.

Gruber HE, Ivey JL, Baylink DJ et al. Long-term calcitonin therapy in postmenopausal osteopo- rosis. Metabolism 1984; 33: 295-303.

MacIntyre I, Stevenson JC, Whitehead MI et al. Calcitonin for the prevention of postmenopaus- al bone loss. Lancet 1988; 2: 1481-3.

Kollerup G, Hermann AP, Brixen K et al. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis. Calcif Tissue Int 1994; 54: 12-15.

Reginster JY, Jupsin I, Deroisy R et al. Prevention of postmenopausal bone loss by rectal calci- tonin. Calcif Tissue Int 1995; 56: 539-42.

Overgaard K, Riis BJ, Christiansen C et al. Nasal calcitonin the treatment of established osteopo- rosis. Clin Endocrinol 1989; 30: 435-42.

Reginster JY, Denis D, Albert A et al. 1-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987; 2: 1481-3.

Overgaard K. Effect of intranasal salmon calci- tonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-re- sponse study. Calcif Tissue Int 1994; 55: 82-6.

Overgaard K, Lindsay R, Christiansen C. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study. Clin Ther 1995; 17: 680-5.

Reginster JY, Denis D, Deroisy R et al. Long-term (3 years) prevention of trabecular postmeno- pausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res 1994; 9: 69-73.

Reginster JY, Deroisy R, Lecart MP et al. A dou- ble-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for pre- vention of postmenopausal lumbar spine bone loss. Am J Med 1995; 98: 452-8.

Ellerington MC, Hillard TC, Whitcroft SI et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996; 59: 6-11.

Silverman SL, Chesnut C, Andriano K et al. Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fractures (VF) in established osteoporosis and has continuous efficacy with prolonged treatment: accrued worldwide data of the PROOF Study. Bone 1998; 23 (Suppl 5): 1108 (abstr).

Chestnut CH III, Silverman S, Andriano K et al. A randomised trial of nasal spray salmon calci- tonin in postmenopausal women with estab- lished osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109: 267-76.

Kanis JA, McCloskey EV. Effect of calcitonin on vertebral and other fractures. Q J Med 1999; 92: 143-9.

Lyritis GP, Paspati I, Karachalios T et al. Pain relief from salmon calcitonin in osteoporotic vertebral crush fractures. A double blind place- bo-controlled clinical study. Acta Orthop Scand 1997; 275: (Suppl): 112-14.

Storm T, Thamsborg G, Sorensen OH, Lund B. The effects of etidronate therapy in postmeno- pausal osteoporotic women: preliminary results. In: Christiansen C, Johansen J, Riis BJ, eds. Osteoporosis. Viborg: Norhaven Bogtrykken A/S, 1987: 1172-6.

Genant HK, Harris ST, Steiger P et al. The effects of etidronate therapy in postmenopausal osteoporotic women: preliminary results. In: Christiansen C, Johansen J, Riis BJ, eds. Osteoporosis. Viborg: Norhaven Bogtrykken A/S, 1987: 1177-81.

Roux C, Oriente P, Laan R et al. Randomized trial of effect of cyclical etidronate in the pre- vention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 1998; 83: 1128-33.

van Staa TP, Abenhaim L, Cooper C. Use of cyclical etidronate and prevention of non-verte- bral fractures. Br J Rheumatol 1998; 36: 1-8.

Valkema R, Papapoulis SE, Vismans F-JFE et al. A four-year continuous gain in bone mass in APD- treated osteoporosis. In: Christiansen C, Johansen J, Riis BJ, eds. Osteoporosis. Viborg: Norhaven Bogtrykken A/S, 1987: 836-9.

Reid IR, Wattie DJ, Evans MC et al. Continuous therapy with pamidronate, a potent bisphospho- nate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994; 79: 1595-9.

Lees B, Garland SW, Walton C et al. Role of oral pamidronate in preventing bone loss in postmenopausal women. Osteoporos Int 1996; 6: 480-5.

Liberman UA, Weiss SR, Broll J et al. The Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43.

Chesnut CH IIIrd, McClung MR, Ensrud KE et al. Alendronate treatment of the postmeno- pausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144-52.

Black DM, Cummings SR, Karpf DB et al. The Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41.

Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and non- vertebral fractures in women with postmeno- pausal osteoporosis: a randomized control trial. JAMA 1999; 282: 1344-52.

Reginster JY, Minne HW, Sorenson OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established osteoporosis. Osteoporos Int 2000; 11: 83-91.

McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-40.

Epstein S. Ibandronate treatment for osteopo- rosis: rationale, preclinical, and clinical develop- ment of extended dosing regimens. Curr Osteoporos Rep 2006; 4: 14-20.

Dando TM, Noble S. Once-monthly ibandronate. Treat Endocrinol 2005; 4: 381-7; discussion 389-90.

Felsenberg D, Miller P, Armbrecht G et al. Oral ibandronate significantly reduces the risk of ver- tebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 2005; 37: 651-4.

Emkey R, Koltun W, Beusterien K et al. Patient preference for once-monthly ibandronate ver- sus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005; 21: 1895-903.

Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-61.

Black DM, Delmas PD, Eastell R et al. Once yearly zoledronic acid for treatment of post- menopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.

Marie PJ, Ammann P, Boivin G et al. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001; 69: 121-9.

Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteo- porosis. N Engl J Med 2004; 350: 459-68.

Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonver- tebral fractures in post-menopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-22.

Kalu DN, Doyle FH, Pennock J, Foster GV. Parathyroid hormone and experimental osteo- sclerosis. Lancet 1970; 1: 1363-6.

Reeve J, Hesp R, Williams D et al. Anabolic effect of low doses of a fragment of human para- thyroid hormone on the skeleton in postmeno- pausal osteoporosis. Lancet 1976; 1: 1035-8.

Reeve J, Meunier PJ, Parsons JA et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. BMJ 1980; 280: 1340-4.

Neer RM, Arnaud CD, Zanchetta AR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.

Lindsay R, Nieves J, Formica C et al. Randomised controlled study of effect of parathyroid hor- mone on vertebral-bone mass and fracture inci- dence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350: 550-5.

Body JJ, Gaich GA, Scheele WH et al. A ran- domized double-blind trial to compare the effi- cacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 4528-35.

Dempster DW, Cosman F, Kurland EH et al. Effects of daily treatment with parathyroid hor- mone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001; 16: 1846-53.

Jiang Y, Zhao JJ, Mitlak BH et al. Recombinant human parathyroid hormone (1-34) [teriparati- de] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18: 1932-41.

Black DM, Greenspan SL, Ensrud KE et al. The effects of parathyroid hormone alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349: 1207-15.

Finkelstein JS, Hayes A, Hunzelman JL et al. The effect of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349: 1216-26.

Cosman F, Nieves J, Woelfert L et al. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998; 13: 1051-5.

Vahle JL, Long GG, Sandusky G et al. Bone neo- plasms in F344 rats given teriparatide [rhPTH(1- 34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004; 32: 426-38.

Beneton MNC, Yates AJP, Rogers S et al. Stanozolol stimulates remodeling of trabecular bone and the net formation of bone at the endocortical surface. Clin Sci 1991; 81: 543-9.

Erdstieck RJ, Pols HA, van Kuijk C et al. Course of bone mass during and after hormone replace- ment therapy with and without addition of nan- drolone decanoate. J Bone Miner Res 1994; 9: 277-83.

Mamelle N, Meunier PG, Dusan R et al. Risk- benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988; 2: 361-5.

Riggs BL, Seeman E, Hodgson SF et al. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis: comparison with conventional therapy. N Engl J Med 1982; 306: 446-50.

Baud CA, Very JM, Courvoisier B. Biophysical studies of bone mineral in biopsies of osteo- porotic patients before and after long-term treatment with fluoride. Bone 1988; 9: 361-5.

Pak CY, Sakhaee K, Adams-Huet B et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 1995; 123: 401-8.

Hedlund IR, Gallagher JC. Increased incidence of hip fracture in women treated with sodium fluo- ride. J Bone Miner Res 1989; 4: 223-5.

Ott SM, Chesnut CH. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 1989; 110: 267-74.

Nordin BEC, Horsman A, Crilly RG et al. Treatment of spinal osteoporosis in postmeno- pausal women. BMJ 1980; 280: 451-4.

Hansen MA. Assessment of age and risk factors on bone density and bone turnover in healthy premenopausal women. Osteoporos Int 1994; 4: 123-8.

Chapuy MC, Chapuy P, Thomas JL et al. Biochemical effects of calcium and vitamin D supplementation in elderly, institutionalized, vitamin D-deficient patients. Rev Rhum Mal Osteoartic (English edn) 1996; 63: 135-40.

Dawson-Hughes B, Harris SS, Krall EA et al. Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D. Am J Clin Nutr 1995; 61: 1140-5.

Lee PE, McElhaney JE, Dian L. Calcium and vita- min D supplementation for the prevention of fractures in postmenopausal women. Aging Health 2006; 2: 241-3.

Dawson-Hughes B, Dallal GE, Krall EA et al. A controlled trial of the effect of calcium supple- mentation on bone density in postmenopausal women. N Engl J Med 1990; 323: 878-83.

Reid IR, Ames RW, Evans MC et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a ran- domized controlled trial. Am J Med 1995; 98: 331-5.

Peacock M, Liu G, Carey M et al. Effect of cal- cium or 25OH vitamin D3 dietary supplementa- tion on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab 2000; 85: 3011-19.

Heaney RP. The role of nutrition in prevention and management of osteporosis. Clin Obstet Gynecol 1987; 50: 833-46.

Chow R, Harrison JE, Notarius C. Effects of two randomized exercise programmes on bone mass of healthy postmenopausal women. BMJ 1987; 295: 1441-4.

Lohman T, Going S, Pamenter R et al. Effects of resistance training on regional and total bone mineral density in premenopausal women: a randomized prospective study. J Bone Miner Res 1995; 10: 1015-24.

Greendale GA, Barrett-Connor E, Edelstein S et al. Lifetime leisure exercise and osteoporosis. The Rancho Bernardo study. Am J Epidemiol 1995; 14: 951-9.

Dalsky GP, Stocke KS, Ehsani AA et al. Weight- bearing exercise training and lumbar bone min- eral content in postmenopausal women. Ann Intern Med 1988; 108: 824-8.

Prudham D, Evans JG. Factors associated with falls in the elderly: a community study. Age Ageing 1981; 10: 141-6.

Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the com- munity. N Engl J Med 1988; 319: 1701-7.

Tinetti ME, Baker DI, McAvay G et al. A multi- factorial intervention to reduce the risk of fall- ing among elderly people living in the community. N Engl J Med 1994; 331: 821-7.

Close J, Ellis M, Hooper R et al. Prevention of falls in the elderly trial (PROFET): a randomised controlled trial. Lancet 1999; 353: 93-7.

Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet 1993; 341: 11-13.

Parker MJ, Gillespie WJ, Gillespie LD. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ 2006; 332: 571-4.

Citron JT, Ettinger B, Genant HK. Prediction of peak premenopausal bone mass using a scale of weighted variables. In: Christiansen C, Johansesn J, Riis BJ, eds. Osteoporosis. Kobenhavn: Osteopress, 1987; 146-9.

Yano K, Wasnich RD, Vogel JM, Heilbrun LK. Bone mineral measurements among middle-aged and elderly Japanese residents in Hawaii. Ann J Epidemiol 1984; 119: 751-64.

Sowers MR, Wallace RD, Lemke JH. Correlates of mid-radius bone density among postmenopausal women: a community study. Am J Clin Nutr 1985; 41: 1045-53.

Kroger H, Tuppurainen M, Honkanen R et al. Bone mineral density and risk factors for osteoporosis -a population-based study of 1600 perimenopaus- al women. Calcif Tissue Int 1994; 55: 1-7.

Bauer DC, Browner WS, Cauley JA et al. The Study of Osteoporosis Fractures Research Group. Factors associated with appendicular bone mass in older women. Ann Intern Med 1993; 118: 657-65.

Wasnich RD, Ross PD, Vogel JM, Maclean CJ. The relative strengths of osteoporotic risk factors in a prospective study of postmenopausal osteoporo- sis. J Bone Miner Res 1987; 2 (Suppl 1): 343.

Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the US Preventive Services Task Force [see comment]. Ann Intern Med 2002; 137: 529-41.

Pesonen J, Sirola J, Tuppurainen M et al. High bone mineral density among perimenopausal women. Osteoporos Int 2005; 16: 1899-906.

Ravnikar A. Compliance with hormone therapy. Am J Obstet Gynecol 1987; 156: 1332-4.

Wallace WA, Price VA, Elliot CA et al. Hormone replacement therapy: acceptability to Nottingham postmenopausal women with a risk factor for osteoporosis. J R Soc Med 1990; 83: 699-701.

Rossouw JE, Anderson GL, Prentice RL et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.

Anderson GL, Limacher M, Assaf AR et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in post- menopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12.

McClung MR, Lewiecki EM, Cohen SB et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821-31.

Sato K. Therapeutic agents for disorders of bone and calcium metabolism. Development of nasal formulation of hPTH (1-34). Clin Calcium 2007; 17: 64-71.